Objective: When an autogenous vein is harvested and used for arterial bypass, it suffers physical and biologic injuries that may set in motion the cellular processes that lead to wall thickening, fibrosis, stenosis, and ultimately graft failure. Whereas the injurious effects of surgical preparation of the vein conduit have been extensively studied, little is known about the influence of the clinical environment of the donor leg from which the vein is obtained.
Within the first 1 to 2 years after implantation of an arterial vein graft, up to 30% fail because of intimal hyperplasia, stenosis, and thrombosis. This deranged and pathologic response to injury is the leading cause of graft failure in these early years. Many research efforts have been applied to understand how the injuries associated with the handling and surgical preparation of a vein graft might affect its later function and evolution into a successful arterial conduit. [1] [2] [3] [4] [5] [6] [7] [8] In fact, the vein conduit is most commonly obtained from the same diseased, ischemic leg that is undergoing bypass. This led us to ask the question, Might the local environment of the leg influence the subsequent response to injury of the vein? Unlike in the previous studies of vein preparation techniques, these clinical factors, which are unique and intrinsic to each patient, have not been examined. To that end, we systematically examined the ex vivo cellular behavior of samples of human saphenous 
METHODS
A prospective, observational study. The patients and veins studied in this report were a subset of a larger, ongoing prospective observational study of patients undergoing elective leg bypass with autogenous vein for indications of peripheral arterial occlusive disease. All elective infrainguinal bypasses using autogenous vein were eligible for study. Exclusion criteria were operations for nonatherosclerotic or aneurysmal disease, concurrent aortobifemoral or femoral-femoral bypass, use of a prosthetic bypass conduit, active treatment for malignant disease (ie, chemotherapy), chronic hemodialysis, perioperative thrombosis of the graft, and a diagnosed systemic inflammatory disease (eg, lupus or other treatment with immunosuppressive drugs) or thrombophilia. The procedures and protocols were approved by the Institutional Review Boards for human studies at the University of Washington and the VA Puget Sound Health Care System, Seattle, Washington. All patients gave their informed consent. The methods for vein harvesting were not prescribed, but all surgeons used the recognized standards of practice, avoiding excessive dissection of the vein and overdistention. At the satisfactory conclusion of the bypass, if the surgeon found that a remnant of harvested saphenous vein was not used (and would have been discarded), this fresh sample was conveyed to our laboratory for study within 2 hours.
Clinical data were recorded prospectively for each patient, including the presence of diabetes, medications, and status of the limb and if the patients were current smokers (within the 30 days before surgery). The preoperative status of the patient's leg in respect to wounds, infection, and ischemia was categorized using the published Wound, Ischemia, and foot Infection (WIfI) definitions. 9, 10 The leg wound and infection classifications were simplified as dichotomous variables (infection, wounds: yes/no). The WIfI ischemia classifications use three different measures to categorize ischemiad ankle-arm index (AAI), absolute ankle pressure, and toe pressuredto more accurately capture the true level of ischemia in diabetics and others with incompressible arteries. For familiarity, this report refers to the AAI cut points of the WIfI scale, although all of the ischemia parameters were used to classify the patients. Ischemia was analyzed as a dichotomous variable (WIfI grades 0 and 1 [AAI > 0.6] vs grades 2 and 3 [AAI < 0.6]) and also as three categories (WIfI grades 0 and 1, AAI $ 0.6; WIfI grade 2, 0.6 > AAI $ 0.4; and WIfI grade 3, AAI < 0.4). The indication for surgery was determined by the Rutherford classification and categorized as claudication or critical limb ischemia (Rutherford 4-6).
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Ex vivo cellular studies. We used an ex vivo model of vascular injury that reliably reflects the major cellular responses to injury that are seen in vivo. 12 The residual segments of fresh saphenous vein were delivered fresh to the laboratory and processed within 2 hours. Details of the processing and testing of the veins and their cells are presented in the Supplementary Methods (online only).
In brief, vein samples were opened longitudinally, the endothelium was removed, and the vein was microdissected to separate the adventitial layer from the intimal-medial layer. 13 An image of this dissection plane can be found in our previous publication. 14 From each vein, these separate, paired layers were prepared into small explants of uniform size (2.5 mm 2 ), placed into culture medium, and observed for 8 days for the outgrowth of cells from the tissue explant. Fifteen to 30 replicate explants were prepared for each vein. Cells were successfully grown from all veins. We quantified the rate of outgrowth of cells from these explants with two parameters: cells per explant and migration-positive explants. To measure cells per explant, on each of 8 days of explant culture, we counted the total number of cells that emerged from the explant (up to a maximum of 100 cells/explant, averaged over the replicates). The metric of cells per explant measures the overall vigor of cell outgrowth from the tissue, a combination of initial migration out of the tissue and subsequent postmigration proliferation. To measure migration-positive explants, on each of 8 days of culture, we counted the percentage of replicates that showed at least one attached, spread cell outside the explant (up to the maximum of 100%). The metric of migration-positive explants is a narrower measure of the migration component of this tissue response to injury. 12, 15, 16 were cultured on opposing sides of a membrane that permitted cell-cell contacts and the diffusion of proteins but not cell migration. Controls included the same cell type on both sides of the membrane. The effect of a different, opposing cell type on growth was calculated as the percentage change in the day 4/day 1 ratio (% change ¼ [(growth ratio with different cell types/ growth ratio of control) À 1]*100). Technical details are provided in the Supplementary Methods (online only).
RNA sequencing. Six pairs of passaged adventitial and medial SMCs were cultured for 2 days in 2% fetal bovine serum, then stimulated with 10 ng/mL of platelet-derived growth factor subunit BB in 2% fetal bovine serum for 24 hours. RNA was harvested, purified, and then sequenced (Supplementary Methods, online only).
Immunohistochemistry. Rings of fresh saphenous veins were formalin fixed, embedded in paraffin, and doubly stained: red for CD34 (a progenitor and endothelial cell marker) and black for CD31 (an endothelial cell marker). The relative areas of red and black staining were quantified from four sample areas in each section and were compared between veins from legs with mild ischemia and veins from legs with severe ischemia (WIfI ischemia grades 0 and 1 vs grades 2 and 3; Supplementary Methods, online only).
Statistical analyses. The patients' clinical characteristics and the ex vivo cellular responses of their veins over time were correlated by two-way repeated measures analysis of variance (ANOVA) using the SPSS statistics package (version 24; IBM, Armonk, NY). An a of .05 was used for statistical significance. Co-culture experiments were analyzed by paired or unpaired t-tests as appropriate. Histologic quantifications were compared with the Mann-Whitney test.
RESULTS
Population characteristics. Fresh samples of the saphenous conduit were collected from 46 patients between 2013 and 2016. All samples were from the great saphenous vein. In three patients, the saphenous vein was harvested from the leg contralateral to the bypass, but in all cases, the clinical characteristics of the donor leg were used for analysis. Table I summarizes the patients' clinical characteristics. The AA genotype of the single nucleotide polymorphism (SNP) À838C>A p27 was present in seven patients (15.2%), which is typical of its general prevalence. 17 Clinical factors associated with cellular outgrowth from the vein. Three significant observations were made in examining the relationships between cellular outgrowth and the patients' clinical factors. First, the cellular outgrowth was significantly faster and more robust from explants of the adventitial layer than from explants of the medial layer of the vein. The global measure of outgrowth (cells per explant) was significantly greater from the adventitial tissue than from the medial tissue (P < .001, two-way ANOVA), and the measure of migration (migration-positive explants) trended in the same direction, especially in the early days of culture (Fig 1) .
Second, the biologic impact of clinical factors (eg, ischemia, smoking) was more pronounced for the adventitial tissues than for the medial tissues. Fig 2 shows that the number of cells per explant from the adventitial tissue was significantly retarded by ischemia, smoking, and presence of leg infection or wounds. In contrast, for the medial tissue, overall outgrowth was retarded only by ischemia and leg infection.
Third, the process of migration from the explants (migration-positive explants) was much less affected by the clinical factors than was the overall measure of cumulative migration and proliferation (cells per explant). None of the clinical factors showed a statistically significant association with the narrower measure of migration alone from the explants (Fig 3) .
In subsequent analyses, we focused on the metric of cells per explant. Among the clinical factors, severe ischemia (WIfI grade 2 or 3), compared with milder ischemia, stood out with the statistically strongest association with the adventitial explants (Fig 2; P < .001, two-way ANOVA). The other factors that were significantly associated with adventitial cell outgrowth were the presence of leg infection, wounds, and smoking ( Fig 2) . The same patterns of outgrowth were borne out by the medial explants, except that smoking and leg wounds did not significantly affect the outgrowth of cells from the media. Age, diabetes, or the p27 SNP (AA vs CC) did not show a significant influence on overall cell outgrowth from either adventitia or media explants (data not shown).
We then analyzed the influence of ischemia on cell outgrowth (cells per explant) with more granularity, employing three gradations of ischemia instead of two: the WIfI grades of 0 and 1 (nominally AAI $ 0.6) vs grade 2 (AAI between 0.59 and 0.4) vs grade 3 (AAI < 0.4). Fig 4 and statistical analysis by two-way ANOVA show that those patients with milder ischemia (WIfI grade of 0 or 1, AAI $ 0.6) grew out significantly more cells than those with all lower AAI categories. There was no difference in cell outgrowth between the more ischemic WIfI grades of 2 and 3. This finding justified our choice of a dichotomous variable for ischemia, that is, WIfI grades 0 and 1 (AAI > 0.6) vs grades 2 and 3 (AAI < 0.6).
To determine the influence of multiple factors, we performed two-way ANOVA analysis of the effect of ischemia (WIfI grades 0 and 1 vs grades 2 and 3) on cells per explant while including all the clinical covariates with a univariate P value of < .2 found in Fig 2, namely, the factors of wounds, infection, and smoking. Table II shows that even after accounting for these other clinical covariables, adventitial cell outgrowth was significantly retarded in the presence of more severe ischemia as well as by smoking and infection. WIfI ischemia grade had the strongest association. In contrast, the outgrowth from medial explants showed a significant association only with ischemia in the multivariable analysis (Table II) .
Characteristics of the cells that grow out from adventitial and medial explants. The cells cultured from the medial and adventitial layers are different. In previous studies, we found that the cells cultured from the medial layer explants are predominantly SMCs because >90% of these cells are smooth muscle a-actin positive.
14 Under phase-contrast microscopy ( Supplementary Fig 1, online only), the outgrowing adventitial cells appeared morphologically similar to SMCs, but the cultured adventitial cells are <10% positive for smooth muscle a-actin.
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The effect of ischemia might be explained by differences in the density of progenitor cells or vasa vasorum in the intact veins. To test this, we performed immunohistochemical studies of whole veins with mild ischemia (WIfI grade 0 or 1; n ¼ 7) and compared them with those with severe ischemia (WIfI grade 2 or 3; n ¼ 8). These were matched for smoking and the other WIfI parameters. Supplementary Fig 2 ( online only) illustrates a typical cross section of vein in which we quantified the prevalence of CD34 þ progenitor cells and endothelial cells within the wall of the veins. We found no differences in the prevalence of progenitor or endothelial cells between mild ischemia and severe ischemia ( Supplementary Fig 3, online only).
To better understand differences between the cells that grow out from the adventitia and media, we measured global gene expression by these cells after stimulation with platelet-derived growth factor. There were 1322 genes differentially expressed between medial and adventitial cells. These were fairly evenly divided: 609 genes were more highly expressed by adventitial cells, and 713 were more highly expressed by SMCs (Supplementary Table I , online only). The genes with the highest fold differences between adventitial cells and SMCs (and with expression levels by at least one cell type in the top 25% of all genes) are presented in Supplementary Table II (online only) . For SMCs, these include inflammatory factors such as interleukin 1b, CXCL8, and CXCL3. For adventitial cells, these include H19, WNT2, WISP2, and PRG4, which are factors involved in development, progenitor cell maintenance or differentiation, and anti-inflammatory, antiarthritic activities. [18] [19] [20] [21] Kyoto Encyclopedia of Genes and Genomes pathway analysis of all of the differentially expressed genes Table III , online only). Kyoto Encyclopedia of Genes and Genomes analysis of the 713 genes more highly expressed by SMCs yielded pathways associated with inflammation and infection; vascular smooth muscle and cardiomyopathy; tumor necrosis factor and cytokine signaling; and nuclear factor kB, phosphatidylinositol 3-kinase/ Akt, and mitogen-activated protein kinase signaling (Supplementary Table III , online only). In summary, the cells arising from the medial tissue show a more inflammatory phenotype compared with those from the adventitia, which express genes associated with development and stem/progenitor cell maintenance.
Influence of clinical factors on the interactions between adventitial cells and SMCs. The data indicate that clinical characteristics that one would assume to be unhealthy for the vein (ie, ischemia, smoking, and infection) are associated with retarded outgrowth of adventitial cells from the vein wall, with ischemia having the strongest association. One interpretation of these findings is that the migration and proliferation of certain adventitial cells could represent a salutary adaptive response to injury, which is inhibited by these detrimental clinical factors. To test this possibility, we cultured adventitial cells and SMCs from the same vein on opposite sides of a filter that prevents cell migration but allows cell contact and the flow of conditioned medium. We observed that the adventitial cells inhibited SMC growth and conversely that SMCs stimulated the growth of adventitial cells (Fig 5) . We also wished to see whether the clinical effects of the leg of origin persisted over time in cell culture. Long-term cultures (passage 6) of the cells propagated from adventitial and intimal-medial explants showed no difference in their primary growth rates according to the degree of ischemia (data not shown), nor did the factor of ischemia status have any influence on the counterinhibitory or stimulatory effects of cultured adventitial cells and SMCs on each other's growth (not shown). However, the factor of smoking appeared to have a sustained effect in the cultured cells: the inhibitory effect of adventitial cells on SMC growth was significantly diminished in smokers (Fig 6, A) . In co-culture experiments, we found that AA genotype SMCs stimulated adventitial cell growth significantly more than the CC genotype. The converse trend was also true, AA adventitial cells inhibited SMC growth more than CC adventitial cells, but that difference did not reach statistical significance (Fig 6, B) . Finally, in this experiment, we confirmed our previous observation 14 that AA adventitial cells grow 
DISCUSSION
We have correlated the clinical characteristics of the patients and their legs from which the saphenous vein was harvested with the ex vivo cellular behavior of the vein components using an ex vivo model that reflects two main vascular responses to injury: initial migration of cells, followed by proliferation of the migrated cells. The chronology and biology of this process have been confirmed in vivo in primates and rodents. 16, 22, 23 Overall, the adventitial layer of the vein showed significantly faster and greater overall outgrowth of cells than the intimal-medial layer, which is similar to what has been observed for porcine arteries. 24 Retarded outgrowth of adventitial cells was associated with the clinical factors of ischemia of the leg, smoking, and presence of infection in the leg. The severity of ischemia in the donor leg was the dominant factor, even after accounting for other clinical factors. In contrast, the outgrowth of SMCs from the medial layer showed a more blunted response to these clinical factors. The responses to ischemia could not be explained by the overall prevalence of CD34 þ progenitor cells or endothelial cells in the vasa vasorum of the intact veins. In addition, of the two metrics we measured, migration (migration-positive explants) was not significantly affected by the clinical factors, whereas the more global measure of migration/proliferation (cells per explant) was more sensitive. This suggests that the initial migratory responses to injury may be less influenced by the deleterious factors of ischemia and smoking, whereas the subsequent proliferative phase of the response to injury is more susceptible to external conditions. Once the cells had grown out from the explants and were cultured, the persistence of clinical effects was variable. The primary growth rates of these cultured cells were no longer influenced by the ischemia of the leg from which they came. However, co-culture of the cells revealed that they reciprocally inhibited and promoted each other's growth: adventitial cells inhibited SMCs, and SMCs promoted growth of adventitial cells. In co-culture, smoking and the genetic trait of the À838C>A p27 SNP showed a lasting influence. Where SMCs promoted adventitial proliferation, the effect was stronger in the protective, AA genotype. Where adventitial cells inhibited SMC proliferation, there was a trend for a larger effect in the AA genotype This study offers two novel perspectives. First, rarely have the clinical characteristics of the patient or the patient's donor leg been correlated with the biologic behavior of cells of the vein conduit. A number of research studies have examined the histologic appearance of the vein before implantation. Some found a correlation between patency and certain preoperative histologic characteristics, such as intimal-medial wall thickening, [25] [26] [27] whereas others have not. 28 Wilson 29 found that the thicker the preoperative medial layer, the more the SMCs proliferated in ex vivo culture. The strong clinical associations between graft patency and the factors of leg ischemia and smoking are well established. [30] [31] [32] In this report, ischemia and smoking were associated with impaired adventitial cell outgrowth. Even though it may take years to recover from some of the harmful biologic effects of smoking after cessation, we may justify our cutoff of 30 days with supportive evidence suggesting that the systemic inflammatory profiles may ameliorate significantly within days to weeks of smoking cessation. 33, 34 The presence of leg infection has not been isolated as a specific risk factor in most clinical studies of vein graft failure, although there is some indirect evidence of an association. 35 Clinical studies have also shown that patients with the AA genotype of the p27 SNP experience superior longterm graft patency. 17 The co-culture experiments show that the AA genotype enhanced SMC promotion of adventitial growth and adventitial inhibition of SMCs, whereas smoking retarded adventitial inhibition of SMCs. The second novel perspective offers a general mechanistic theory: that a healthy, adaptive response to vascular injury may include increased activity of certain cells arising from the adventitia. Contrary to the conventional wisdom that all cellular proliferation and migration in response to vascular injury lead inevitably to intimal hyperplasia and stenosis, the migration and proliferation of certain adventitial cells may be a salutary response. Previous studies have shown that murine and porcine adventitial cells do migrate to the intima of vein grafts, [36] [37] [38] as has been observed for injured arteries. 39 Historically, it has been assumed that these adventitial cells pathologically contribute to intimal hyperplasia. However, support for a beneficial role for adventitial cells comes from Betz et al, 40 who reported that adventitial cells inhibited SMC migration and proliferation in arterial tissue explants, and from the results of Barker et al, 41 which also suggest an inhibitory effect of the adventitia on intimal hyperplasia. Our observations that ischemia inhibits adventitial cell outgrowth and that adventitial cells inhibit SMC proliferation are consistent with the hypothesis that certain adventitial cells may play a protective role by inhibiting the proliferation of SMCs, the dominant actors in intimal hyperplasia and graft failure. 42 Our data suggest that the effects of ischemia may predominate in the proliferative phase of the response to injury, not in the initial migration of cells. We do not yet know the identity of the adventitial cells that migrate from adventitial tissue in these experiments, given the cellular heterogeneity of the adventitia. However, the adventitial cells are distinctly different from the medial SMCs. The adventitial cells are predominantly smooth muscle a-actin negative, whereas the SMCs are predominantly positive.
14 Compared with the adventitial cells, the SMCs overexpress genes in the areas of inflammation and infection; tumor necrosis factor and cytokine signaling; and nuclear factor kB, phosphatidylinositol 3-kinase/Akt, and mitogen-activated protein kinase signaling. In contrast, the adventitial cells dominate in the expression of gene families associated with development and stem/progenitor cell maintenance. These characteristics suggest the possibility that CD34 þ progenitor cells give rise to the migrating adventitial cells. The CD34 þ progenitor cell has been shown to possess immunomodulatory, anti-inflammatory, and tissue repair properties. [43] [44] [45] [46] The human venous CD34 þ progenitor cell, like the cultured adventitial cell of this study, does not express smooth muscle a-actin within the vein or after in vitro culture. 47 This distinguishes these progenitor cells from other major cell types that populate the adventitia: SMCs, pericytes, and endothelial cells (after endothelialmesenchymal transition). However, the challenge of identifying the source of the migrating adventitial cell is made more difficult by the fact that progenitor cells (as well as other vascular cells) change their phenotype once they emerge from the tissue and are cultured, losing their CD34 expression. 47 Only in genetically modified animal models has it been possible to track the true origins of cells from different vascular layers, as they change their phenotypes in response to injury. 48 This study has important limitations. We do not yet know which resident adventitial cells migrate from the tissue in response to injury. This is the subject of our ongoing work. Although the deleterious clinical factors we have identified are well known to impair graft patency, we cannot directly link graft patency with the measures of cellular outgrowth in this small sample. The microdissection technique separating the vein layers always leaves a small portion of the media with the adventitial layer, but this failing should blunt rather than accentuate the differences we found between the responses of the two layers. The majority of the veins were derived from white men with relatively normal renal function, so we cannot make any inferences about the roles of sex, race, or kidney function. In the case of leg bypass surgery, some of the clinical factors can be interdependent. For example, the presence of wounds, infection, and degree of ischemia may sometimes be linked.
An extremely large sample size would be needed to define the independent effects of these different factors or the gradations of severity of wounds or foot infection. Vein harvest techniques are known to influence endothelial function, and although good practice standards were applied in the surgical harvest of the veins, those techniques were not standardized for this study. All but three of the bypass conduits were resected and reimplanted (three were done with the in situ technique). In the majority of cases, the remnant of vein furnished for research was the most distal end of the vein, in keeping with the standard practice of conserving the portion of conduit with the largest diameter. We would argue that the ex vivo injury model used here represents a relatively severe injury in comparison to the subtleties of harvest technique, especially considering that we remove the luminal endothelium in processing. In spite of the heterogeneity of harvesting techniques, all of the potentially deleterious clinical effects, such as ischemia and smoking, lead in the same direction of impaired adventitial cell outgrowth.
CONCLUSIONS
From the study of 46 human vein grafts, we have found that cells grow out from the adventitial tissue more vigorously than from the media and are more susceptible to the negative effects of leg ischemia as well as smoking and leg infection. These adventitial cells have distinctly different gene expression profiles. If adventitial cells do play an important role in the vein's response to injury, this understanding opens the door to exploration of novel therapeutic approaches to prevent graft stenosis and to improve patency by targeting the responsible adventitial cells. Our continuing focus will be on these adventitial cells, their origins within the adventitial layer, and their modulation of the response to injury. Vein bypass grafting remains an important mainstay of revascularization for patients with advanced limb ischemia. Midterm failure of vein grafts occurs in 30% to 40% of patients and generally is manifested as a flow-reducing stenosis within the body of the venous conduit or at the anastomotic regions. On histologic evaluation, these lesions are fibroproliferative in nature, with pronounced neointimal thickening that may be extremely focal or more diffuse. Risk factors for vein graft failure are poorly understood and only partially overlap those for atherosclerosis (eg, smoking and thrombophilic states). Harvest and implantation injury, ischemiareperfusion, acute inflammatory responses, and hemodynamic factors are known to be important contributors. The adaptation of veins to the arterial environmentd described as the "arterialization" responsedrequires active tissue remodeling in response to a profound change in biomechanical forces. Understanding the drivers of adaptive vs maladaptive venous remodeling is central to developing new approaches to predict and to prevent vein graft failure. 1 Sobel and colleagues conducted a prospective observational study to examine how local and systemic factors influence cellular responses from saphenous veins harvested for bypass surgery. Their study is of interest because they examined the influence of three clinical factorsdsmoking, degree of limb ischemia, and presence of infectiondon the outgrowth of cells from the medial and adventitial layers of the vein. The authors identified that each of these factors had a notable impact on cellular outgrowth from the vein, with the effects being more pronounced in the adventitial cells. Moreover, adventitial cells tended to exert an inhibitory influence on medial vascular smooth muscle cells, an effect that was blunted in smokers. Finally, they examined the relationship of these cellular behaviors to a single nucleotide polymorphism of the p27 gene that had been previously identified as a candidate marker for graft patency, 2 finding a positive association with the protective (AA) p27 genotype and co-culture effects between these cell types. Although largely ignored in much of traditional vascular biology, the role of the adventitia in vascular homeostasis and response to injury has been increasingly appreciated. 3 Situated at the external interface between the graft and the surrounding tissue environment, the adventitia integrates local tissue signals, such as hypoxia, infection, and sterile inflammation, and is a target for host response through a rich microvascular network. The adventitia contains a mixed population of cells including fibroblasts and progenitor/stemlike cells. Experimental studies have demonstrated that adventitial cells migrate inward to participate in neointima formation and that "constrictive remodeling" secondary to adventitial fibrosis is an important contributor to restenosis in both arteries and veins. The contribution by Sobel and colleagues provides further evidence that adventitial cell function may be central to vein graft disease and suggests direct connections to local (ischemia), systemic (smoking), and genetic (p27 SNP) factors. An important limitation of their study is a lack of correlation with the in vivo healing response. Previous clinical studies from our group demonstrated that early outward remodeling of the vein is an important predictor of downstream graft patency. 4 Further studies are needed to establish an integrated model of normal and abnormal vein graft adaptation and the specific role of key contributing cell types during the phases of vein graft healing.
AUTHOR CONTRIBUTIONS
The opinions or views expressed in this commentary are those of the authors and do not necessarily reflect the opinions or recommendations of the Journal of Vascular Surgery or the Society for Vascular Surgery.
SUPPLEMENTARY METHODS (online only).
Ex vivo cellular studies. During surgery, all vein specimens were kept in buffered saline (shown to be the best solution 1 ). After the surgeon had identified the remnant specimen, it was placed into Dulbecco modified Eagle medium (Gibco, ThermoFisher Scientific, Waltham, Mass) with 10 mM HEPES, pH 7.4, while still in the operating room. Veins were maintained at room temperature during prompt transit to the laboratory, and processing began within 2 hours. After removal of periadventitial fat, veins were opened longitudinally. We excluded sections with surgical marker dyes or valve segments. The endothelium was removed, and the vein was microdissected to separate the adventitial layer from the intimal-medial layer (see this published reference for an image of this dissection 49 ). Explants of uniform size (2.5 mm 2 ) were prepared separately from the intimal-medial and adventitial layers, using a customized McIlwain tissue chopper (The Mickle Laboratory Engineering Co Ltd, Surrey, United Kingdom). Depending on the specimen size, a minimum of 15 to 30 replicate explants were prepared from each vein and maintained in 25-cm 2 flasks (15 explants/flask) with 1.2 mL of 20% fetal bovine serum (FBS; Atlanta Biologicals, Atlanta, Ga)/Dulbecco modified Eagle medium (changed three times/week). We quantified the outgrowth of cells from these tissue explants using a grid reticle and cell counter ( Supplementary Fig 1) . Cells were successfully grown from all vein explants. Two parameters were used to quantify the rate and quantity of cellular outgrowth: cells per explant and migration-positive explants. Cells per explant represent the number of cells that emerged from each tissue explant on each of 8 days of culture. A maximum of 100 cells per explant was counted to minimize error. Migration-positive explants represent the percentage of replicates that demonstrated at least one attached, spread cell outside the explant, enumerated on each of 8 days of culture. The metric of cells per explant is a measure of the overall vigor of cell outgrowth from the tissue, a combination of initial migration and postmigration proliferation. The metric of migration-positive explants is a pure measure of migration. [2] [3] [4] When cells around the explants became confluent (2-3 weeks), the medium was changed to Smooth Muscle Cell Growth Medium (Cell Applications, Inc, San Diego, Calif), which contains 5% FBS and undisclosed amounts of epidermal growth factor, fibroblast growth factor 2, insulin, and heparin (James Yu, Cell Applications, personal communication). This medium was also used for later studies of the resulting propagated cell lines on collagen-coated plasticware (10 mg/mL of bovine skin collagen [BD Biosciences, ThermoFisher Scientific] in phosphate-buffered saline overnight at 4 C). Immunohistochemistry. Rings of saphenous veins were formalin fixed and embedded in paraffin for immunohistochemical staining. All steps for immunohistochemistry were performed on a Leica Bond (Leica Microsystems Inc, Buffalo Grove, Ill) using the Leica Supplementary Fig 1 (online only) . Representative phase-contrast images (magnification Â100) of cells migrating from saphenous vein adventitial (upper panel) and medial (lower panel) explants after 8 days in culture. SMCs, Smooth muscle cells. Supplementary Fig 2 (online only) . Photomicrograph of saphenous vein double stained for CD34 (red) and CD31 (black; magnification Â40) illustrating the quantification area (dotted line rectangle). CD34 þ progenitor cells and the endothelial cells located in the vasa vasorum were quantified. At least four such boxes were sampled for each section. The arrow indicates an example of endothelium in the vasa vasorum. A higher power view (magnification Â200) is shown in the inset.
Bond Polymer Detection Kit (Leica Microsystems #DS9800). Tissue sections were double stained for CD31 (5.0 mg/mL clone JC70A MO823; Dako, Carpinteria, Calif) and CD34 (1.0 mg/mL QBEND 10, M7165; Dako) with black and red chromagens, respectively. In this way, endothelial cells in the vasa vasorum, which are positive for both CD34 and CD31, are black (ie, red blocked by the black), and the CD34 þ /CD31
À progenitor cells are red.
Nonimmune immunoglobulin G1 (X0931, Dako) was used as a negative control, which yielded no signal. Slides were scanned in brightfield using the NanoZoomer Digital Pathology System (Hamamatsu Photonics, Hamamatsu City, Japan). The digital images were then imported into the Visiopharm (Hoersholm, Denmark) quantitative digital pathology platform. To determine the relative areas of black and red staining, at least four boxes per section were drawn from just below the luminal surface (to avoid luminal endothelium) to the edge of the adventitia ( Supplementary  Fig 2) . Aggregate data ( Supplementary Fig 3) are presented as the ratio of black or red area to total area of the boxes. Results were tested using the Mann-Whitney test (Prism 6; GraphPad Software Inc, La Jolla, CA). Supplementary Fig 3 (online only) . CD34 þ progenitor cells and endothelial cells within the vasa vasorum of the vein as illustrated in Supplementary Figure 2 were quantified. Comparing their prevalence in saphenous veins of mild ischemia (n ¼ 7; Wound, Ischemia, and foot Infection [WIfI] grades 0 and 1) with those with severe ischemia (n ¼ 8; WIfI grades 2 and 3) matched for smoking, leg wounds, and infection, there are no significant differences (endothelial cells not shown). The boxes represent 25th and 75th percentiles; solid lines, the medians; and dashed lines, the means. Supplementary Fig 4 (online only) . Effect of the p27 single nucleotide polymorphism (SNP) genotype on the proliferation of adventitial cells (left) and smooth muscle cells (SMCs; right) when co-cultured with the same cell type. Values are the mean 6 standard error of the mean of nine and eight paired adventitial cells and SMCs for the AA and CC genotypes, respectively. *P < .001, AA vs CC. 
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